Dr. Lal PathLabs Limited

NSEI:LALPATHLAB Rapport sur les actions

Capitalisation boursière : ₹272.6b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Dr. Lal PathLabs Résultats passés

Passé contrôle des critères 6/6

Dr. Lal PathLabs a connu une croissance annuelle moyenne de ses bénéfices de 7.8%, tandis que le secteur Healthcare a vu ses bénéfices augmenter de en hausse à 28.4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 12.4% par an. Le rendement des capitaux propres de Dr. Lal PathLabs est 20.5% et ses marges nettes sont de 16.7%.

Informations clés

7.8%

Taux de croissance des bénéfices

7.6%

Taux de croissance du BPA

Healthcare Croissance de l'industrie29.4%
Taux de croissance des recettes12.4%
Rendement des fonds propres20.5%
Marge nette16.7%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

Recent updates

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Feb 13
Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dec 29
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

Sep 21
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11
Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

May 25
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?

Apr 28
Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?

Ventilation des recettes et des dépenses

Comment Dr. Lal PathLabs gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NSEI:LALPATHLAB Recettes, dépenses et bénéfices (INR Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2422,8753,8154,2270
31 Mar 2422,2663,5774,1350
31 Dec 2321,7223,2983,8560
30 Sep 2321,2273,0133,7720
30 Jun 2320,5522,6382,8690
31 Mar 2320,1692,3883,5770
31 Dec 2220,1142,4353,3490
30 Sep 2220,1892,4803,2990
30 Jun 2219,8352,7133,2550
31 Mar 2220,8743,4483,4800
31 Dec 2120,3293,6693,3030
30 Sep 2119,8844,0413,2640
30 Jun 2119,2193,9443,1260
31 Mar 2115,8132,9162,5010
31 Dec 2014,5202,4072,3430
30 Sep 2013,2752,0032,1600
30 Jun 2012,6121,9552,0790
31 Mar 2013,3042,2592,2220
31 Dec 1913,2982,4052,5400
30 Sep 1912,9442,3222,4930
30 Jun 1912,4632,0862,4120
31 Mar 1912,0341,9922,3410
31 Dec 1811,6911,9232,2940
30 Sep 1811,3931,8252,2380
30 Jun 1810,9991,7612,1730
31 Mar 1810,5691,7072,1020
31 Dec 1710,1001,6178980
30 Sep 179,5481,5658080
30 Jun 179,3891,5867520
31 Mar 179,1241,5461,6940
31 Dec 168,9021,5767000
30 Sep 168,7131,8766760
30 Jun 168,2491,4136250
31 Mar 167,9131,3225800
31 Dec 157,6541,2012,15211
31 Mar 156,5969084970
31 Mar 145,5797631,75510

Des revenus de qualité: LALPATHLAB a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de LALPATHLAB (16.7%) sont supérieures à celles de l'année dernière (12.8%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de LALPATHLAB ont augmenté de 7.8% par an au cours des 5 dernières années.

Accélération de la croissance: La croissance des bénéfices de LALPATHLAB au cours de l'année écoulée ( 44.6% ) dépasse sa moyenne sur 5 ans ( 7.8% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices LALPATHLAB au cours de l'année écoulée ( 44.6% ) a dépassé celle du secteur Healthcare 29.5%.


Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de LALPATHLAB ( 20.5% ) est considéré comme élevé.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé